Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Messing

Showing results (111-120 of 199) with videos related to

Pageof 20
Sort By:
Molecular Cancer Research : MCR|September 15, 2007
Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsivenessHuei-Ju Ting, Bo-Ying Bao, Jay E Reeder, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 2, 2015
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Agata Ptaszynska, Samuel M Cohen, Edward M Messing, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 3, 2011
Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experienceJennifer Gordetsky, Jennifer Findeis-Hosey, Erdal Erturk, et al.
Translational Andrology and Urology|July 10, 2023
Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage eraJiping Zeng, Joel Funk, Benjamin R Lee, et al.
IRB|September 1, 1988
Follow-up: recontacting subjects in mutagen exposure monitoring studiesDavid B Busch, George T Bryan, Douglas Easterling, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 2, 2017
The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatoryDavid Horovitz, Yifan Meng, Jean V Joseph, et al.
Human Pathology|July 15, 2017
Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomyMatthew Truong, Soroush Rais-Bahrami, Jeffrey W Nix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their diseaseEdward M Messing, Ralph Madeb, Changyong Feng, et al.
The Journal of Urology|July 11, 2003
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomasXi Na, Guan Wu, Charlotte K Ryan, et al.
Plos One|July 15, 2021
Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapyHong Zhang, Christopher Doucette, Hongmei Yang, et al.
Pageof 20

Showing results (111-120 of 199) with videos related to

Sort By:
Pageof 20
Molecular Cancer Research : MCR|September 15, 2007
Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsivenessHuei-Ju Ting, Bo-Ying Bao, Jay E Reeder, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 2, 2015
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Agata Ptaszynska, Samuel M Cohen, Edward M Messing, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 3, 2011
Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experienceJennifer Gordetsky, Jennifer Findeis-Hosey, Erdal Erturk, et al.
Translational Andrology and Urology|July 10, 2023
Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage eraJiping Zeng, Joel Funk, Benjamin R Lee, et al.
IRB|September 1, 1988
Follow-up: recontacting subjects in mutagen exposure monitoring studiesDavid B Busch, George T Bryan, Douglas Easterling, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 2, 2017
The role of urinary cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumour biopsy is nonconfirmatoryDavid Horovitz, Yifan Meng, Jean V Joseph, et al.
Human Pathology|July 15, 2017
Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomyMatthew Truong, Soroush Rais-Bahrami, Jeffrey W Nix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their diseaseEdward M Messing, Ralph Madeb, Changyong Feng, et al.
The Journal of Urology|July 11, 2003
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomasXi Na, Guan Wu, Charlotte K Ryan, et al.
Plos One|July 15, 2021
Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapyHong Zhang, Christopher Doucette, Hongmei Yang, et al.
Pageof 20